Chargement en cours...
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis
BACKGROUND: Rifapentine has potent activity against Mycobacterium tuberculosis but the optimal dose for tuberculosis treatment is unknown. OBJECTIVE: to determine antimicrobial activity, safety, and tolerability of rifapentine 450 mg or 600 mg administered daily during the first 8 weeks of pulmonary...
Enregistré dans:
| Publié dans: | Int J Tuberc Lung Dis |
|---|---|
| Auteurs principaux: | , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6783281/ https://ncbi.nlm.nih.gov/pubmed/26056101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.14.0868 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|